EUVIMEDEUVIMED entdecken
Crossref

Clinical features, treatment, and outcomes of patients with carfilzomib induced thrombotic microangiopathy

Weilun Fang, Wei Sun, Weijin Fang, Shaoli Zhao, Chunjiang Wang

International Immunopharmacology · 2024-06 · 134 · 112178

DOI: 10.1016/j.intimp.2024.112178 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Immunopharmacology, 2024-06. Verfasst von Weilun Fang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, The Third Xiangya Hospital, Central South University, Changsha, Hunan 410013, China; College of Pharmacy, Changsha Medical Un…. Hauptthemen laut MEDLINE: Thrombotic Microangiopathies, Oligopeptides. Die Arbeit wurde bisher 81-mal zitiert (Crossref) und nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Thrombotic microangiopathy (TMA) is associated with carfilzomib, and knowledge of carfilzomib-induced TMA is based mainly on case reports. This study investigated the clinical characteristics of patients with carfilzomib-induced TMA and provided a reference for the rational use of carfilzomib. METHODS: Reports of carfilzomib-induced TMA were collected for retrospective analysis by searching the Chinese and English databases from inception to January 31, 2024. RESULTS: Sixty-six patients were included, with a median age of 63 years (range 39, 85). The median time to onset of TMA was 42 days (range 1, 1825) from initial administration, and the median number of cycles was 3 cycles (range 1, 15). Hemolytic anemia was recorded in 64 patients, with a median of 8.3 g/dL (range 4.6, 13). Sixty-three patients had thrombocytopenia with a median of 18 × 109/L (range 1, 139). The median value of increased LDH was 1192 IU/L (range 141, 5378). ADAMTS13 activity was normal in 41 (62.1 %) of the 42 patients. Mutations were found in 9 (13.6 %) of the 15 patients. Fifty-seven patients achieved a clinical response after discontinuing carfilzomib and receiving therapeutic plasma exchange (53.0 %), eculizumab (24.2 %), or hemodialysis (39.4 %). CONCLUSION: Carfilzomib-induced TMA is an important adverse event that should be considered in patients receiving carfilzomib for multiple myeloma with anemia, thrombocytopenia, and acute kidney injury. Withdrawal of carfilzomib and treatment with eculizumab have proven successful in some patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Thrombotic MicroangiopathiesOligopeptidesHumansMaleMiddle AgedFemaleAgedAdultRetrospective StudiesAged, 80 and overTreatment OutcomeADAMTS13 ProteinMultiple MyelomaAntibodies, Monoclonal, HumanizedThrombocytopenia

Stichwörter der Autor:innen

Atypical hemolytic uremia syndromeCarfilzomibEculizumabTherapeutic plasma exchangeThrombotic microangiopathy

Substanzen

carfilzomibOligopeptidesADAMTS13 ProteinADAMTS13 protein, humanAntibodies, Monoclonal, Humanizedeculizumab

Autor:innen und Institutionen

  • Department of Pharmacy, The Third Xiangya Hospital, Central South University, Changsha, Hunan 410013, China; College of Pharmacy, Changsha Medical University, Changsha, Hunan 410219, China.
  • Department of Pharmacy, The Third Xiangya Hospital, Central South University, Changsha, Hunan 410013, China.
  • Department of Endocrinology, The Third Xiangya Hospital, Central South University, China.
  • Department of Pharmacy, The Third Xiangya Hospital, Central South University, Changsha, Hunan 410013, China. Electronic address: wongcj@csu.edu.cn.

Zitieren

APA

Fang, W., Sun, W., Fang, W., Zhao, S., & Wang, C. (2024). Clinical features, treatment, and outcomes of patients with carfilzomib induced thrombotic microangiopathy. International Immunopharmacology, 134, 112178. https://doi.org/10.1016/j.intimp.2024.112178

Vancouver

Fang W, Sun W, Fang W, Zhao S, Wang C. Clinical features, treatment, and outcomes of patients with carfilzomib induced thrombotic microangiopathy. International Immunopharmacology. 2024;134:112178. doi:10.1016/j.intimp.2024.112178

BibTeX
@article{Fang2024,
  author = {Fang, Weilun and Sun, Wei and Fang, Weijin and Zhao, Shaoli and Wang, Chunjiang},
  title = {Clinical features, treatment, and outcomes of patients with carfilzomib induced thrombotic microangiopathy},
  journal = {International Immunopharmacology},
  year = {2024},
  volume = {134},
  pages = {112178},
  doi = {10.1016/j.intimp.2024.112178}
}
Kostenlos starten →